2. Apoptosis Anti-infection
  3. Caspase HIV
  4. Q-VD-OPh

Q-VD-OPh  (Synonyms: QVD-OPH; Quinoline-Val-Asp-Difluorophenoxymethylketone)

製品番号: HY-12305 純度: 99.90%
COA 取扱説明書 Technical Support

Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1135695-98-5

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 122 在庫あり
Solution
10 mM * 1 mL in DMSO USD 122 在庫あり
Solid
1 mg $60 在庫あり
5 mg $108 在庫あり
10 mg $180 在庫あり
25 mg $288 在庫あり
50 mg $528 在庫あり
100 mg $850 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 103 publication(s) in Google Scholar

Other Forms of Q-VD-OPh:

Q-VD-OPh 関連抗体

Top Publications Citing Use of Products

顧客検証

WB
Cell Proliferation/Viability Assay
Apoptosis Analysis
RT-PCR

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Nature. 2025 Apr;640(8060):1062-1071.  [Abstract]

    Control or VDAC2-deficient B16-OVA tumour cells were treated with or without IFNγ (in the presence of the pan caspase inhibitor Q-VD-Oph (40 μM, 24 h) to inhibit cell death of VDAC2-deficient cells) for 24 h, or control cells were treated with ABT-737 (BCL-2 inhibitor) + S63845 (MCL-1 inhibitor) + Q-VD-OPh (pan-caspase inhibitor) (A + S group) for 6 h.

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9.  [Abstract]

    RT-qPCR for p53 target genes in two independent isogenic non-targeting sgRNA control (NTC) and Trp53 KO Eμ-Myc lymphoma cell lines pre-treated with QVD-O-Ph (25 mM, 15 min), then S63845 for indicated time points. Fold change is relative to 0 h for each cell line.

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9.  [Abstract]

    RTqPCR for the p53 target genes PUMA and P21 in parental DOHH2 and two independently derived Rho0 cell lines. Cells were pre-treated with the caspase inhibitor QVD-O-Ph (HY-12305), and then treated with 100 nM S63845 for 24 h or, as a comparator for potent p53 activation, treated with 10 µM of the MDM2 inhibitor Nutlin-3a (HY-10029) for 24 h. Ct values for each gene are normalized to the housekeeping gene HMBS, and fold change is shown relative to the DMSO-treated parental cell sample. Error bars represent S.E.M. for two independent experiments.

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9.  [Abstract]

    Immunoblotting for p53 and PUMA in parental DOHH2 lymphoma cells and two independently derived Rho0 cell lines. Cells were pre-treated with QVD-O-Ph (HY-12305), and then treated with 100 nM S63845 or, as a control for potent p53 stabilization, treated with 10 µM Nutlin-3a (HY-10029) for 24 h. Blotting for HSP70 was used as a loading control. Representative blot shown from three independent experiments. Quantifications of p53 protein levels from three independent immunoblotting experiments are shown, relative to HSP70. Error bars represent S.D.

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Nature. 2023 Mar;615(7950):158-167.  [Abstract]

    Cell viability assessment in Tbk1-null B16 cells pre-treated with RIPK3 inhibitor (HS-1371, 2 μM) or MLKL inhibitor (GW806742X, 5 μM) and the pan-caspase inhibitor Q-VD-Oph (20 μM) +/− TNFα/IFNγ for 9 days (n=6, 2 independent experiments: 2-way ANOVA, Dunnett’s multiple comparisons test).

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2022 Aug;29(8):1486-1499.  [Abstract]

    Flow cytometry of CD4 and CD8 T cells expressing caspase activity in the absence (Med) or presence of Q-VD-Oph (Q-VD) (10 μM) (Top). Inhibition of caspase activity (preventive effect) in the presence of IDN-6556 (10 μM), VX-765 (10 μM), Q-VD and MCC950. Percentages were calculated as follows: (Med-Inh/Med)*100. Each dot represents one individual (Middle). Flow cytometry of CD4 and CD8 T cells expressing annexin V in the absence (Med) or presence of Q-VD (Bottom).

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2021 May;18(5):1186-1196.  [Abstract]

    Control and VDAC1-deficient MLFs (1×106) were stimulated with Q-VD-OPh (A/Q) (10 μM each), infected with HSV-1 or EMCV (MOI=1) for 6h prior to qPCR analysis of the indicated genes. The data shown are the mean±SD from one representative experiment performed in triplicate. ns nonsignificant; *P < 0.05; ***P < 0.001 (unpaired t-test)

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2019 May;110(5):1746-1759.  [Abstract]

    Cells are treated with RA in the presence or absence of the caspase inhibitor Q-VD-OPh, and cleaved caspase-3 and caspase-8 and total and cleaved PARP were analyzed.

    Caspase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

    HIV アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    HIV HIV-1 HIV-2

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.

    IC50 & Target[1]

    Caspase-7

    48 nM (IC50)

    Caspase-3

    25-400 nM (IC50)

    Caspase-1

    25-400 nM (IC50)

    Caspase-8

    25-400 nM (IC50)

    Caspase-9

    25-400 nM (IC50)

    Caspase-10

    25-400 nM (IC50)

    Caspase-12

    25-400 nM (IC50)

    体外実験

    Q-VD-OPh is a potent inhibitor of caspase-7 with an IC50 of 48 nM utilizing a cell-free assay consisting of human recombinant caspase-7, Q-VD-OPh, and the substrate AMC-DEVD-pNa[1]. Q-VD-OPh fully inhibits caspase-3 and -7 activity at 0.05 μM. Caspase-8 is also inhibited at low Q-VD-OPh concentrations. The cleavage of PARP-1 is fully prevented at 10 μM Q-VD-OPh. DNA fragmentation and disruption of the cell membrane functionality are both prevented at 2 μM Q-VD-OPh[2]. Q-VD-OPh is significantly more effective in preventing apoptosis than the widely used inhibitors, ZVAD-fmk and Boc-D-fmk, and is also equally effective in preventing apoptosis mediated by the three major apoptotic pathways, caspase 9/3, caspase 8/10, and caspase12. Q-VD-OPh is not toxic to cells even at extremely high concentrations[3]. QVD is also able to increase the expression of differentiation markers in acute myeloid leukemia (AmL) blasts. QVD alone or combined with VDDs increases differentiation and HPK1-cJun signaling in AmL cell context-dependent manner[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Q-VD-OPh 関連抗体
    体内実験

    Chronic treatment with Q-VD-OPh prevents caspase-7 activation and limits the pathological changes associated with tau, including caspase cleavage. Q-VD-OPh could be a potential therapeutic compound for the treatment of Alzheimer's disease[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    513.49

    分子式

    C26H25F2N3O6
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O)C[C@H](NC([C@@H](NC(C1=NC2=CC=CC=C2C=C1)=O)C(C)C)=O)C(COC3=C(F)C=CC=C3F)=O
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 100 mg/mL (194.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9475 mL 9.7373 mL 19.4746 mL
    5 mM 0.3895 mL 1.9475 mL 3.8949 mL
    10 mM 0.1947 mL 0.9737 mL 1.9475 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.92%

    COA (247 KB) HNMR (267 KB) LCMS (91 KB) Elemental Analysis Report (107 KB)

    取扱説明書 (2659 KB)
    参考文献
    動物実験
    [1]

    Mouse: Stock solutions of Q-VD-OPh are prepared in DMSO and diluted in sterile PBS solution prior to injection. A final concentration of 10 mg/kg is chosen indicating neuroprotection at this concentration of Q-VD-OPh. Three-month old mice are divided into two groups: control, vehicle (n=3) or treated (n=2). Mice are injected i.p. three times a week with either Q-VD-OPh or vehicle for a total time period of 3 months[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9475 mL 9.7373 mL 19.4746 mL 48.6864 mL
    5 mM 0.3895 mL 1.9475 mL 3.8949 mL 9.7373 mL
    10 mM 0.1947 mL 0.9737 mL 1.9475 mL 4.8686 mL
    15 mM 0.1298 mL 0.6492 mL 1.2983 mL 3.2458 mL
    20 mM 0.0974 mL 0.4869 mL 0.9737 mL 2.4343 mL
    25 mM 0.0779 mL 0.3895 mL 0.7790 mL 1.9475 mL
    30 mM 0.0649 mL 0.3246 mL 0.6492 mL 1.6229 mL
    40 mM 0.0487 mL 0.2434 mL 0.4869 mL 1.2172 mL
    50 mM 0.0389 mL 0.1947 mL 0.3895 mL 0.9737 mL
    60 mM 0.0325 mL 0.1623 mL 0.3246 mL 0.8114 mL
    80 mM 0.0243 mL 0.1217 mL 0.2434 mL 0.6086 mL
    100 mM 0.0195 mL 0.0974 mL 0.1947 mL 0.4869 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Q-VD-OPh Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Q-VD-OPh1135695-98-5QVD-OPH Quinoline-Val-Asp-DifluorophenoxymethylketoneCaspaseHIVHuman immunodeficiency virusInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Q-VD-OPh
    製品番号:
    HY-12305
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.